Institutional members access full text with Ovid®

Share this article on:

Dissecting the HIV-specific immune response: a systems biology approach

Peretz, Yoava; Cameron, Cherylb; Sékaly, Rafick-Pierrea,b

Current Opinion in HIV and AIDS: January 2012 - Volume 7 - Issue 1 - p 17–23
doi: 10.1097/COH.0b013e32834ddb0e

Purpose of review Several unique HIV-infected or HIV-resistant cohorts have been studied over the years to try and delineate the correlates of protection. Although several mechanisms have been put forward, studies aiming to integrate the different mechanisms into a comprehensive model are still lacking. Current systems biology approaches emphasize the importance of unifying independent datasets, provide tools that facilitate hypothesis formulation and testing, and direct us toward uncovering novel therapeutic targets by defining molecular networks perturbed during disease. This review will focus on the current findings that utilized systems biology techniques in order to identify correlates of protection from HIV disease progression and resistance to infection in unique cohorts of individuals as well as in nonhuman primate models of SIV infection.

Recent findings Using systems biology technologies and data analysis tools, the studies described herein have found that pathways implicated in survival, cell cycling, inflammation, and oxidative stress work in unison to limit pathology caused by chronic immune activation. This situation favors the survival of effector lymphocytes and limits the dissemination of viral particles in HIV elite controllers, exposed-uninfected individuals, and natural hosts of SIV infection.

Summary Systems and computational biology tools have clearly expanded our understanding of HIV pathogenesis by unifying independent observations and by giving us novel molecular targets to pursue. These molecular signatures have the potential to uncover correlates of protection in HIV disease and, in the era of personalized medicine, to determine predictive signatures of treatment efficacy and/or failure.

aImmuneCarta Services, Montreal, Quebec, Canada

bVaccine and Gene Therapy Institute-Florida (VGTI-FL), Port Saint-Lucie, Florida, USA

Correspondence to Rafick-Pierre Sékaly, 11350 SW Village Parkway, Port Saint-Lucie, FL 34987, USA. Tel: +1 772 345 4780; fax: +1 772 345 3675; e-mail:

© 2012 Lippincott Williams & Wilkins, Inc.